C. Russell Trenary III - Mar 20, 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
CEO AND PRESIDENT, Director
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Mar 20, 2024
Transactions value $
$0
Form type
4
Date filed
3/22/2024, 05:00 PM
Previous filing
Apr 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +455K $0.00 455K Mar 20, 2024 Common Stock 455K $6.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.